

Coronary Stents–Pipeline Insight and Competitive Landscape, 2022

<https://marketpublishers.com/r/C06BB606A4D3EN.html>

Date: January 2022

Pages: 60

Price: US\$ 3,500.00 (Single User License)

ID: C06BB606A4D3EN

Abstracts

This report can be delivered to the clients within 4-5 Business Days

DelveInsight's, "Coronary Stents–Pipeline Insight and 2022," report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Coronary Stents pipeline landscape. Owing to the rise in the prevalence of coronary artery diseases (CAD), the coronary stents market is witnessing remarkable growth. Significant players are focusing on expanding their geographical reach, for dominating the current market.

According to the Centre for Disease Control and Prevention, about one-third of the population in the U.S. is obese. The change in lifestyle such as physical inactivity, smoking, drinking, and mistimed and unhealthy food habits are among the major reasons leading to health problems such as obesity, hypertension, arterial blockage, and others. Therefore, owing to all this, there is a significant rise in the pipeline of coronary stents recently.

This reports provides a detailed study of the emerging coronary stents devices along with competitive landscape to help better understand the market.

Geography Covered

Global coverage

Coronary Stents: Overview

Coronary Stents: Understanding

Coronary stents are small, wire, mesh tubes that help widen a clogged artery and restore adequate blood flow to the heart. During the procedure, the cardiologist places the stent over a thin, long tube with a balloon tip called a catheter and inserts it into an artery in the groin or arm. Once the stent reaches the clogged artery, the doctor will inflate the balloon to expand the stent. When the stent reaches the desired size to widen the clogged artery, the doctor will deflate and remove the balloon. The stent will stay in place permanently to help prop open the artery and decrease its chance of narrowing again. Over time, the inner lining of the artery will grow over the surface of the stent, making it a permanent part of the artery.

Types of Coronary Stents

Bare-Metal Stents: These are tiny wire mesh tubes that help widen a clogged artery, but are not coated with a polymer or drugs to help prevent re-blockage of the artery. This type of stent may be used in patients who are allergic to either the polymer or drugs used in drug-eluting stents.

Drug-Eluting Stents: A drug-eluting stent is a bare-metal stent that has been coated with a polymer that gradually releases a drug over time when re-blockage is most likely to happen. This helps reduce the chance of the artery becoming blocked again. There are two types of drug-eluting stents: Permanent Polymer Drug-Eluting Stent and Bioabsorbable Polymer Drug-Eluting Stent.

Coronary Stents: Competitive Assessment

This segment of the coronary stents devices pipeline report encloses its detailed analysis of various pipeline devices which include product description, licensing and collaboration details and other developmental activities including the latest news and press releases. The report also provides a list of major players involved in the pipeline product development.

Product Type

The coronary stents are segmented on the basis of product – Bare Metal Stents (BMS), Drug Eluting Stents (DES) and Bioresorbable Vascular Scaffolds (BVS).

Product Biomaterial

Coronary Stents can be divided based upon the biomaterials – Metallic (Cobalt Chromium (CoCr), Platinum Chromium (Pt-Cr), Stainless Steel, Nickel Titanium), Polymeric Biomaterial and Natural Biomaterial.

Major Players in Coronary Stents

There are approx. 20+ key companies which are developing the products for Coronary Stents.

Cre8 EVO: Alvimedica

Cre8 EVO is a highly innovative Drug Eluting Stent (DES) that is designed to face the clinical outcome challenges when treating patients undergoing percutaneous coronary intervention. That is what Cre8 EVO is; a DES born from the most innovative technology to date. It is manufactured by CID S.p.A. member of Alvimedica group. It has received CE approval and is currently not available in US and Japan. The company is also evaluating safety, efficacy and deliverability of the CRE8 sirolimus-eluting stent system in the treatment of patients with de novo coronary artery lesions.

ArterioSorb: Arterius

ArterioSorb is an innovative medical implant product currently being developed by Arterius, a UK medical device micro/SME, to treat coronary artery disease (CAD). It is a next-generation bioresorbable cardiovascular scaffold (BRS, stent), ArterioSorb, to be implanted within the coronary arteries in order to open blocked vessels, and to biodegrade within two years when healing is complete and it is no longer needed. Arterius will perform the in-vitro and in-vivo studies necessary to demonstrate the safety and efficacy of ArterioSorb. After completion of this study, the company will enter the First-in-Man trials and commercialization process.

Further product details are provided in the report.....

Coronary Stents: Competitive Benchmarking

This segment of the reports provides analysis of the pipeline report to give a clear understanding of the comparative analysis.

The analysis is based on

Brand Positioning of Leading companies

Application

Industry Collaborations

Coronary Stents: Commercialization Activity

This segment of the report provides a detailed list of any commercial activity in the field of coronary stents ranging from collaboration, mergers and acquisition, recent breakthrough among others.

Development Activities

In the year 2018, Abbott received the approval from the United States Food and Drug Administration (USFDA) for a new generation coronary stent system, named as XIENCE Sierra.

In April 2019, The National Pharmaceutical Pricing Authority (NPPA) of India has approved a hike in the price of coronary stents, with the bare metal stents now priced at ₹8,261 (exclusive of GST) as against the existing ₹7,660. Drug eluting/biodegradable stents cost ₹30,080 (exclusive of GST) as against ₹27,890.

Further commercial activities are provided in the report.....

Coronary Stents: Reimbursement

US

As part of drug-eluting stent programs, medical device companies are proactively identifying strategies to help reduce the lag time between the anticipated introduction of drug-eluting stents and appropriate reimbursement for procedures using them. For example, Boston Scientific is working with hospitals to assess the potential impact of drug-eluting stents on cardiovascular practices as hospitals consider the potential impact of this technology into their service mix. Hospitals and Boston Scientific are evaluating the potential effects of drug-eluting stents within the hospital at multiple levels, including: Procedure Disease Cardiac Catheterization Lab Cardiovascular Unit Hospital Health Care Systems The company has completed a series of analyses that consider the economic drivers relevant to hospitals' use of drug-eluting stents, including possible changes in resource use (immediate stenting procedure, reintervention rate, and shifts to and from other services, including coronary artery bypass graft), as well as the costs and clinical outcomes associated with these resources. The purpose of these analyses is to estimate the effect of drug-eluting stents in order to support reimbursement from insurers, as well as to assist providers in resource use and practice management.

Further information is provided in the report.....

Report Highlights

Extensive coverage of the Coronary Stents under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Coronary Stents and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

The report consists of in depth analysis of pipeline products based on various

parameters

Coronary Stents Report Insights

Coronary Stents - Pipeline Analysis

Coronary Stents - Unmet Need

Coronary Stents - Market Dynamics

Coronary Stents - Future Perspectives and Conclusion

Coronary Stents - Analyst Views

Key Questions

What are significant companies in this segment, their information, analysis, and insights to improve R&D strategies?

How to identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage?

What are important and diverse types of Coronary Stents under development?

What are market-entry and market expansion strategies in Coronary Stents?

What are some of the mergers and acquisitions and to identify major players with the most promising pipeline?

What is in-depth analysis of the product's current stage of development, territory and estimated launch date?

Key Players

REVA Medical Inc

Rontis AG

S3V Vascular Technologies

Sahajanand Medical Technologies Pvt Ltd

Shanghai Bio-heart Biological Technology Co Ltd

Stentys SA

Svelte Medical Systems Inc

Tepha Inc

Terumo Corp

TissueGen Inc

TrendyMED Inc.

VasoTech Inc.

Viller Scientific LLC

Vornia Biomaterials Ltd

Xenogenics Corporation

Biotronik AG

Cardionovum GmbH

Concept Medical Inc

Contego Medical LLC

Cordis Corp

DISA Vascular (Pty) Ltd

Elixir Medical Corp

Envision Scientific Pvt Ltd

Aachen Resonance GmbH

Abbott Vascular Inc

Adcomp Technologies Inc.

Aeon Bioscience

AlviMedica Medical Technologies Inc

Amaranth Medical Inc

Arterius Ltd

Atrium Medical Corp

Bactiguard Holding AB

Bionext Biotech Products Ltd.

Biosten, LLC

Systems, Inc.

ID Nest Medical SAS

InspireMD Inc

Japan Stent Technology Co., Ltd.

JW Medical Systems Ltd

Kaneka Corp

Kyoto Medical Planning Co Ltd

Liaoning Biomedical Materials R&D Center Co Ltd

Lifetech Scientific (Shenzhen) Co Ltd

MangoGen Pharma Inc

Manli Cardiology Ltd

Medinol Ltd

Medtronic plc

Miami Cardiovascular Innovations

Micell Technologies Inc

MicroPort Scientific Corp

Minvasys SAS

MIV Therapeutics Inc

NanoCoeur, Inc.

Nanova, Inc

Nesstent Ltd.

Nexeon MedSystems Inc

NuVascular Technologies Inc

OrbusNeich

Pediasent LLC

QualiMed Innovative Medizinprodukte GmbH

Qvanteq AG

Relisys Medical Devices Ltd

Contents

1. KEY INSIGHTS

2. CORONARY STENTS: SNAPSHOT

3. CORONARY STENTS

- 3.1. Product Overview
- 3.2. Regulatory Approvals based on Class
- 3.3. Indications
- 3.4. Mechanism

4. CORONARY STENTS: PRODUCT ASSESSMENT

- 4.1. Assessment by Product Type
 - 4.1.1. Bare Metal Stents (BMS)
 - 4.1.2. Drug Eluting Stents (DES)
 - 4.1.3. Bioresorbable Vascular Scaffolds (BVS)
- 4.2. Assessment by Product Biomaterial
- 4.3. Assessment by Company
 - 4.3.1. Alvimedica
 - 4.3.1.1. Cre8 EVO: Alvimedica
 - 4.3.1.1.1. Product Information
 - 4.3.1.1.2. Research and Development
 - 4.3.1.1.3. Patent Details
 - 4.3.1.1.4. Regulatory Milestone
 - 4.3.2. Arterius
 - 4.3.2.1. ArterioSorb: Arterius
 - 4.3.2.1.1. Product Information
 - 4.3.2.1.2. Research and Development
 - 4.3.2.1.3. Patent Details
 - 4.3.2.1.4. Regulatory Milestone

*More Companies and products would be added in the final report

5. CORONARY STENTS: COMPETITIVE BENCHMARKING : BY COMPANY

- 5.1. Brand Positioning of Leading companies
- 5.2. Analysis based on Application

5.3. Analysis based on Industry Collaborations

6. CORONARY STENTS – COMMERCIALIZATION ACTIVITY

6.1. Collaboration

6.2. Licensing

6.3. Merger and Acquisition

6.4. Recent Breakthrough

6.5. Literature Studies

6.6. KOL Views

7. CORONARY STENTS: REGULATORY

7.1. US

7.2. Europe

7.3. Japan

8. CORONARY STENTS: REIMBURSEMENT

8.1. Case Study - US

8.2. Case Study - Europe

8.3. Case Study -Japan

9. CORONARY STENTS: MARKET DYNAMICS

9.1. Unmet Needs

9.2. Market Drivers

9.3. Market Barriers

10. DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

10.1. PEST Analysis

10.2. Future Growth Perspectives

11. CONCLUSION

12. APPENDIX

12.1. Research Methodology

12.1.1. Coverage

12.1.2. Secondary Research

13. BIBLIOGRAPHY

14. DELVEINSIGHT CAPABILITIES

15. DISCLAIMER

16. ABOUT DELVEINSIGHT

I would like to order

Product name: Coronary Stents–Pipeline Insight and Competitive Landscape, 2022

Product link: <https://marketpublishers.com/r/C06BB606A4D3EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C06BB606A4D3EN.html>